NasdaqGS · Biotechnology

Y-mAbs Therapeutics (YMAB)

Stock, pipeline and biotech catalyst intelligence

$8.61Price unavailableCached market snapshot

Market cap$391.2M

Cash$62.3M

Quarterly burn$4.4M

Pipeline assets7

Short float9.8%

Clinical portfolio

Y-mAbs Therapeutics Drug Pipeline

Showing 1 of 7

Asset	Indication	Stage	Milestone	Signals ?
GD2-SADA	Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma	Phase 1	Dec 31, 2026	—

Continue with BioPharma ProUnlock 6 additional programs and complete development details.

Upcoming milestones

1 currently tracked

Dec 31, 2026

Phase 1

Melanoma, Small cell lung cancer, Sarcoma, Neuroblastoma

Data readout

Event details

Company profile

Y-mAbs Therapeutics is a biotechnology company in the healthcare sector.

Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.